# XWELL, Inc.: financial statements, quarterly

XWEL · Nasdaq · CIK 1410428 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xwel.md) · [Financials](/companies/xwel/financials.md) · [Filings](/companies/xwel/filings.md) · [Insiders](/companies/xwel/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xwel/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [7.5](/filings/0001558370-24-015707.md) | [7.4 d](/filings/0001558370-25-004851.md) | [8.7](/filings/0001558370-25-008028.md) | [9.3](/filings/0001558370-25-011581.md) | [8.4](/filings/0001104659-25-112636.md) | [7.5 d](/filings/0001104659-26-038330.md) | [7.0](/filings/0001104659-26-064495.md) | [7.7](/filings/0001104659-26-097169.md) | [7.3](/filings/0001104659-25-112636.md) | [7.2 d](/filings/0001104659-26-038330.md) | [6.6](/filings/0001104659-26-064495.md) | [7.1](/filings/0001104659-26-097169.md) |
| Cost of revenue | $m | [6.4](/filings/0001558370-24-015707.md) | [6.5 d](/filings/0001558370-25-004851.md) | [6.1](/filings/0001558370-25-008028.md) | [6.2](/filings/0001558370-25-011581.md) | [6.4](/filings/0001104659-25-112636.md) | [6.3 d](/filings/0001104659-26-038330.md) | [5.7](/filings/0001104659-26-064495.md) | [5.9](/filings/0001104659-26-097169.md) | [5.9](/filings/0001104659-25-112636.md) | [4.2 d](/filings/0001104659-26-038330.md) | [4.3](/filings/0001104659-26-064495.md) | [4.2](/filings/0001104659-26-097169.md) |
| Gross profit | $m | [1.1](/filings/0001558370-24-015707.md) | [0.9 d](/filings/0001558370-25-004851.md) | [2.7](/filings/0001558370-25-008028.md) | [3.1](/filings/0001558370-25-011581.md) | [2.1](/filings/0001104659-25-112636.md) | [1.1 d](/filings/0001104659-26-038330.md) | [1.3](/filings/0001104659-26-064495.md) | [1.8](/filings/0001104659-26-097169.md) | [1.5](/filings/0001104659-25-112636.md) | [2.9 d](/filings/0001104659-26-038330.md) | [2.4](/filings/0001104659-26-064495.md) | [2.9](/filings/0001104659-26-097169.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [3.0](/filings/0001558370-24-015707.md) | [2.7 d](/filings/0001558370-25-004851.md) | [4.2](/filings/0001558370-25-008028.md) | [4.7](/filings/0001558370-25-011581.md) | [6.4](/filings/0001104659-25-112636.md) | [4.8 d](/filings/0001104659-26-038330.md) | [4.3](/filings/0001104659-26-064495.md) | [4.3](/filings/0001104659-26-097169.md) | [1.6](/filings/0001104659-25-112636.md) | [5.9 d](/filings/0001104659-26-038330.md) | [7.6](/filings/0001104659-26-064495.md) | [4.7](/filings/0001104659-26-097169.md) |
| Operating income | $m | [(12.1)](/filings/0001558370-24-015707.md) | [(5.1) d](/filings/0001558370-25-004851.md) | [(2.4)](/filings/0001558370-25-008028.md) | [(1.9)](/filings/0001558370-25-011581.md) | [(4.8)](/filings/0001104659-25-112636.md) | [(7.7) d](/filings/0001104659-26-038330.md) | [(3.2)](/filings/0001104659-26-064495.md) | [(2.7)](/filings/0001104659-26-097169.md) | [(0.8)](/filings/0001104659-25-112636.md) | [(9.1) d](/filings/0001104659-26-038330.md) | [(5.4)](/filings/0001104659-26-064495.md) | [(2.1)](/filings/0001104659-26-097169.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001104659-26-097169.md) | [0.0](/filings/0001104659-25-112636.md) | [(0.0) d](/filings/0001104659-26-038330.md) | not reported | [0.1](/filings/0001104659-26-097169.md) |
| Net income | $m | [(11.5)](/filings/0001558370-24-015707.md) | [(5.0) d](/filings/0001558370-25-004851.md) | [(2.5)](/filings/0001558370-25-008028.md) | [(2.0)](/filings/0001558370-25-011581.md) | [(4.8)](/filings/0001104659-25-112636.md) | [(7.6) d](/filings/0001104659-26-038330.md) | [(4.7)](/filings/0001104659-26-064495.md) | [(2.3)](/filings/0001104659-26-097169.md) | [(0.7)](/filings/0001104659-25-112636.md) | [(9.3) d](/filings/0001104659-26-038330.md) | [(11.2)](/filings/0001104659-26-064495.md) | [(2.2)](/filings/0001104659-26-097169.md) |
| Diluted EPS | $ per share | [(2.76)](/filings/0001558370-24-015707.md) | not reported | [(0.60)](/filings/0001558370-25-008028.md) | [(0.48)](/filings/0001558370-25-011581.md) | [(0.99)](/filings/0001104659-25-112636.md) | not reported | [(1.00)](/filings/0001104659-26-064495.md) | [(0.56)](/filings/0001104659-26-097169.md) | [(0.26)](/filings/0001104659-25-112636.md) | not reported | [(1.51)](/filings/0001104659-26-064495.md) | [(0.26)](/filings/0001104659-26-097169.md) |
| Basic EPS | $ per share | [(2.76)](/filings/0001558370-24-015707.md) | not reported | [(0.60)](/filings/0001558370-25-008028.md) | [(0.48)](/filings/0001558370-25-011581.md) | [(0.99)](/filings/0001104659-25-112636.md) | not reported | [(1.00)](/filings/0001104659-26-064495.md) | [(0.56)](/filings/0001104659-26-097169.md) | [(0.26)](/filings/0001104659-25-112636.md) | not reported | [(1.51)](/filings/0001104659-26-064495.md) | [(0.26)](/filings/0001104659-26-097169.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.8](/filings/0001558370-24-005211.md) | [8.4](/filings/0001558370-25-004851.md) | [4.3](/filings/0001544784-24-000083.md) | [5.4](/filings/0001558370-24-012235.md) | [4.4](/filings/0001558370-24-015707.md) | [4.6](/filings/0001104659-26-038330.md) | [3.7](/filings/0001558370-25-008028.md) | [5.3](/filings/0001558370-25-011581.md) | [4.0](/filings/0001104659-25-112636.md) | [2.6](/filings/0001104659-26-097169.md) | [16.8](/filings/0001104659-26-064495.md) | [11.8](/filings/0001104659-26-097169.md) |
| Current assets | $m | [30.0](/filings/0001558370-24-005211.md) | [26.6](/filings/0001558370-25-004851.md) | [24.5](/filings/0001544784-24-000083.md) | [23.1](/filings/0001558370-24-012235.md) | [19.5](/filings/0001558370-24-015707.md) | [15.3](/filings/0001104659-26-038330.md) | [14.8](/filings/0001558370-25-008028.md) | [11.8](/filings/0001558370-25-011581.md) | [10.8](/filings/0001104659-25-112636.md) | [5.9](/filings/0001104659-26-097169.md) | [19.7](/filings/0001104659-26-064495.md) | [15.1](/filings/0001104659-26-097169.md) |
| Total assets | $m | [42.9](/filings/0001558370-24-005211.md) | [39.0](/filings/0001558370-25-004851.md) | [37.5](/filings/0001544784-24-000083.md) | [36.3](/filings/0001558370-24-012235.md) | [33.8](/filings/0001558370-24-015707.md) | [25.4](/filings/0001104659-26-038330.md) | [24.8](/filings/0001558370-25-008028.md) | [22.4](/filings/0001558370-25-011581.md) | [21.7](/filings/0001104659-25-112636.md) | [11.2](/filings/0001104659-26-097169.md) | [25.0](/filings/0001104659-26-064495.md) | [20.5](/filings/0001104659-26-097169.md) |
| Current liabilities | $m | [8.2](/filings/0001558370-24-005211.md) | [9.3](/filings/0001558370-25-004851.md) | [9.2](/filings/0001544784-24-000083.md) | [10.4](/filings/0001558370-24-012235.md) | [9.9](/filings/0001558370-24-015707.md) | [9.2](/filings/0001104659-26-038330.md) | [8.9](/filings/0001558370-25-008028.md) | [9.5](/filings/0001558370-25-011581.md) | [10.1](/filings/0001104659-25-112636.md) | [12.9](/filings/0001104659-26-097169.md) | [8.4](/filings/0001104659-26-064495.md) | [6.7](/filings/0001104659-26-097169.md) |
| Total liabilities | $m | [17.3](/filings/0001558370-24-005211.md) | [18.0](/filings/0001558370-25-004851.md) | [18.7](/filings/0001544784-24-000083.md) | [19.1](/filings/0001558370-24-012235.md) | [19.0](/filings/0001558370-24-015707.md) | [17.6](/filings/0001104659-26-038330.md) | [21.4](/filings/0001558370-25-008028.md) | [18.3](/filings/0001558370-25-011581.md) | [18.3](/filings/0001104659-25-112636.md) | [23.8](/filings/0001104659-26-097169.md) | [14.9](/filings/0001104659-26-064495.md) | [12.3](/filings/0001104659-26-097169.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [17.8](/filings/0001558370-24-005211.md) | [13.0](/filings/0001558370-25-004851.md) | [10.6](/filings/0001544784-24-000083.md) | [8.8](/filings/0001558370-24-012235.md) | [6.3](/filings/0001558370-24-015707.md) | [(0.8)](/filings/0001104659-26-038330.md) | [(5.8)](/filings/0001558370-25-008028.md) | [(5.2)](/filings/0001558370-25-011581.md) | [(6.3)](/filings/0001104659-25-112636.md) | [(22.3)](/filings/0001104659-26-097169.md) | [0.4](/filings/0001104659-26-064495.md) | [(1.9)](/filings/0001104659-26-097169.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,255) d](/filings/0001558370-24-015707.md) | [(3,201) d](/filings/0001558370-25-004851.md) | [(3,682)](/filings/0001558370-25-008028.md) | [(443) d](/filings/0001558370-25-011581.md) | [(3,416) d](/filings/0001104659-25-112636.md) | [(3,464) d](/filings/0001104659-26-038330.md) | [(4,178)](/filings/0001104659-26-064495.md) | [(2,386) d](/filings/0001104659-26-097169.md) | [(2,107) d](/filings/0001104659-25-112636.md) | [(42.0) d](/filings/0001104659-26-038330.md) | [(4,602)](/filings/0001104659-26-064495.md) | [(4,515) d](/filings/0001104659-26-097169.md) |
| Capital expenditure | $k | [404 d](/filings/0001558370-24-015707.md) | [266 d](/filings/0001558370-25-004851.md) | [291](/filings/0001558370-25-008028.md) | [353 d](/filings/0001558370-25-011581.md) | [410 d](/filings/0001104659-25-112636.md) | [729 d](/filings/0001104659-26-038330.md) | [424](/filings/0001104659-26-064495.md) | [889 d](/filings/0001104659-26-097169.md) | [945 d](/filings/0001104659-25-112636.md) | [706 d](/filings/0001104659-26-038330.md) | [390](/filings/0001104659-26-064495.md) | [169 d](/filings/0001104659-26-097169.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,731](/filings/0001558370-23-019060.md) | [4,167](/filings/0001544784-24-000083.md) | [4,171](/filings/0001558370-24-012235.md) | [4,174](/filings/0001558370-24-015707.md) | [4,183](/filings/0001558370-25-008028.md) | [4,183](/filings/0001558370-25-011581.md) | [4,819](/filings/0001104659-25-112636.md) | [5,261](/filings/0001104659-26-064495.md) | [5,417](/filings/0001104659-26-097169.md) | [5,761](/filings/0001104659-25-112636.md) | [7,396](/filings/0001104659-26-064495.md) | [8,487](/filings/0001104659-26-097169.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 8,589,266 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001104659-26-097169.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.